• Product NameTriflusal
• Brief DescriptionInhibitors
• Purification95.00%
• Biological ActivityTriflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA).
• Target NamePDE inhibitor; PPAR antagonist
• CAS No. 322-79-2
• Calculated MW 248.16
• Formulation C10H7F3O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O
  Pathways:Metabolism
  Receptor:PDE; TXA2R
  Boling pt:316C?
  Melting pt:
  Solubility:Ethanol: 50 mg/mL (201.48 mM); DMSO: 50 mg/mL (201.48 mM)
  Appearance:White Crystal
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Acta Crystallographica Section A, 49 ( Pt 1), 10-22 (1993)

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting